|
Patient #
|
Study arm
|
Soft tissue mets. at baseline
|
Bone mets. at baseline
|
IRAE greater than Gr 1a (week of occurrence)
|
Progression-free survival (weeks)
|
|---|
|
1
|
1
|
Yes
|
Yes
|
None
|
24
|
|
2
|
1
|
Yes
|
Yes
|
None
|
48
|
|
3
|
1
|
No
|
Yes
|
None
|
24
|
|
4
|
1
|
Yes
|
No
|
None
|
48+
|
|
5
|
1
|
Yes
|
Yes
|
None
|
16
|
|
6
|
1
|
No
|
Yes
|
Hyperthyroidism (6); Hypothyroidism (12)
|
24
|
|
7
|
2
|
No
|
Yes
|
Hypothyroidism (36)
|
36+
|
|
8
|
2
|
Yes
|
Yes
|
Pancreatitis (30)
|
48
|
|
9
|
2
|
Yes
|
Yes
|
None
|
24
|
|
10
|
2
|
Yes
|
Yes
|
None
|
24+
|
|
11
|
2
|
No
|
Yes
|
Hyperthyroidism (18)
|
48
|
|
12
|
2
|
No
|
Yes
|
Adrenal Insufficiency (38)
|
72+
|
|
13
|
3
|
Yes
|
Yes
|
Elevated TSH (9)
|
36+
|
|
14
|
3
|
Yes
|
No
|
None
|
24
|
|
15
|
3
|
Yes
|
Yes
|
None
|
24
|
|
16
|
3
|
Yes
|
No
|
Hyperthyroidism (3)
|
12
|
|
17
|
3
|
No
|
Yes
|
None
|
12
|
- aImmune-related adverse events that were at least possibly related to pembrolizumab and /or pTVG vaccine are listed
